Search Medical Condition
Please enter condition
Please choose location from dropdown

Nyack, New York Clinical Trials

A listing of Nyack, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (425) clinical trials

MammaPrint BluePrint and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

The FLEX Registry will include all patients with stage I-III breast cancer who have received MammaPrint and BluePrint testing in any clinical setting. Study arm appendices will specify treatment arm, inclusion criteria, and number of patients needed. Approximately 2000 patients from 70-75 US based institutions will be enrolled. Treatment is ...

Phase N/A

0.0 miles

Learn More »

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy Surgery and/or Radiation Therapy

This is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily) in early stage node-positive HER2 negative breast cancer patients. Patients will be randomized 1:1 within stratum defined by: Hormone Receptor status (HR positive vs HR negative), body mass index (<30 vs 30 kg/m2) and stage (Stage ...

Phase

0.0 miles

Learn More »

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

Phase

0.0 miles

Learn More »

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

PRIMARY OBJECTIVES: I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy. SECONDARY OBJECTIVES: I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention ...

Phase

0.0 miles

Learn More »

Topical Treatment for Sexual Pain Vulvar Pain in Postmenopausal Women Not Taking Estrogens or Similiar Hormones. Women on Aromatase Inhibitors or Tamoxifen CAN Enter the Clinical Trial

Topical Veregen (15% sinecatechins) is an FDA approved botanical drug derived from green tea and is approved to be used as multiple doses, three times a day to treat all visible external genital warts. Topical green tea ointment has been shown to alleviate pain and improve wound healing in the ...

Phase

0.0 miles

Learn More »

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.

Phase

0.0 miles

Learn More »

A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP

This study will assess the ability of eltrombopag to induce sustained treatment-free remission in ITP subjects who relapsed or failed to respond to an initial treatment with steroids. There is limited, mainly retrospective evidence that earlier use of eltrombopag after ITP diagnosis, will allow a larger proportion of subjects to ...

Phase

0.0 miles

Learn More »

CemiplimAb Survivorship Epidemiology

The objectives of the study are: To identify potential determinants of disease progression, Quality of life (QOL), and other health-related outcomes for patients with Cutaneous squamous cell carcinoma (CSCC) undergoing treatment with cemiplimab To assess patient experience, including QOL and functional status, in a real-world setting for patients with CSCC ...

Phase N/A

0.0 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 24 weeks. Patients will be instructed to ...

Phase

0.0 miles

Learn More »

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.

Phase

0.0 miles

Learn More »